keyword
MENU ▼
Read by QxMD icon Read
search

Ribavirin

keyword
https://www.readbyqxmd.com/read/29147645/real-world-cure-rates-for-hepatitis-c-virus-treatments-that-include-simeprevir-and-or-sofosbuvir-are-comparable-to-clinical-trial-results
#1
Kian Bichoupan, Neeta Tandon, James F Crismale, Joshua Hartman, David Del Bello, Neal Patel, Sweta Chekuri, Alyson Harty, Michel Ng, Keith M Sigel, Meena B Bansal, Priya Grewal, Charissa Y Chang, Jennifer Leong, Gene Y Im, Lawrence U Liu, Joseph A Odin, Nancy Bach, Scott L Friedman, Thomas D Schiano, Ponni V Perumalswami, Douglas T Dieterich, Andrea D Branch
AIM: To assess the real-world effectiveness and cost of simeprevir (SMV), and/or sofosbuvir (SOF)-based therapy for chronic hepatitis C virus (HCV) infection. METHODS: The real-world performance of patients treated with SMV/SOF ± ribavirin (RBV), SOF/RBV, and SOF/RBV with pegylated-interferon (PEG) were analyzed in a consecutive series of 508 patients with chronic HCV infection treated at a single academic medical center. Patients with genotypes 1 through 4 were included...
November 12, 2017: World Journal of Virology
https://www.readbyqxmd.com/read/29145802/effectiveness-of-current-and-future-regimens-for-treating-genotype-3-hepatitis-c-virus-infection-a-large-scale-systematic-review
#2
Hosnieh Fathi, Andrew Clark, Nathan R Hill, Geoffrey Dusheiko
BACKGROUND: Six distinct genetic variants (genotypes 1 - 6) of hepatitis C virus (HCV) exist globally. Certain genotypes are more prevalent in particular countries or regions than in others but, globally, genotype 3 (GT3) is the second most common. Patients infected with HCV GT1, 2, 4, 5 or 6 recover to a greater extent, as measured by sustained virological response (SVR), following treatment with regimens based on direct-acting antivirals (DAAs) than after treatment with older regimens based on pegylated interferon (Peg-IFN)...
November 16, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29142571/in-vitro-transcription-analysis-of-ns5a-from-hcv-3a-circulating-in-pakistani-patients-with-chronic-hepatitis-c-and-their-differential-response-to-antiviral-therapy
#3
Shameem Bhatti, Sobia Manzoor, Fahed Parvaiz, Javed Ashraf, Farakh Javed
Objective: Mutations in HCV nonstructural protein 5A (NS5A) play a vital role in virus resistance. The aim of this study was to develop a correlation between NS5A mutations (genotype 3a) and virological response towards interferon alpha (IFN-α) plus ribavirin therapy. Methods: In this study, which was conducted from 09-02-2013 to 25-11-2015 in the rural area of Province Sindh - Pakistan, total patients' responses to peg-IFN therapy were investigated. Patients were given peg-IFN therapy for 24 to 48 weeks and categorized as sustained virologic responders (SVR) or non-responders (NR) to HCV infection...
September 2017: Pakistan Journal of Medical Sciences Quarterly
https://www.readbyqxmd.com/read/29141246/evaluation-of-temporal-virological-responses-to-interferon-%C3%AE-2b-plus-ribavirin-among-genotype-3a-hepatitis-c-virus-infected-patients
#4
Abida Raza, Muhammad Ovais, Hafsa Aziz, Asim Anwar, Javaid Irfan, Irshad Ahmad, Muhammad Mukhtar
OBJECTIVES: The present study aimed to examine the impact of rapid virological response (RVR) and early virological response (EVR) on sustained virological response (SVR) in chronic hepatitis C genotype 3a individuals. METHODS: The patients were given antiviral therapy with IFN-α-2b, 3 million units 3 times a week and 800-1,200 mg of ribavirin daily adjusted to the patient's body weight (<60 kg 800 mg day-1, and >60 kg 1,200 day-1). The patients received this combination therapy for 24 weeks...
November 16, 2017: Intervirology
https://www.readbyqxmd.com/read/29137590/a-closing-chapter-hepatitis-c-genotype-3-elimination-in-liver-transplant-sofosbuvir-daclatasvir-in-a-hard-to-treat-population
#5
Eva Maria Teegen, Brigitta Globke, Eckart Schott, Johann Pratschke, Dennis Eurich
OBJECTIVES: Historically, hepatitis C virus genotype 3 infection has not been as hard to treat as genotype 1 using interferon-based therapy. Now, genotype 3 infection can be treated using interferon-free regimes such as the combination of sofosbuvir and daclatasvir, which is a highly successful and reliable therapeutic option before liver transplant. However, real world data are rather limited regarding the use of antivirals (sofosbuvir/daclatasvir) for hepatitis C virus genotype 3 recurrence after liver transplant...
November 15, 2017: Experimental and Clinical Transplantation
https://www.readbyqxmd.com/read/29136329/follow-up-of-sustained-virologic-responders-with-hepatitis-c-and-advanced-liver-disease-after-interferon-ribavirin-free-treatment
#6
Karin Kozbial, Stephan Moser, Ramona Al-Zoairy, Remy Schwarzer, Christian Datz, Rudolf Stauber, Hermann Laferl, Michael Strasser, Sandra Beinhardt, Albert Friedrich Stättermayer, Michael Gschwantler, Heinz Zoller, Andreas Maieron, Ivo Graziadei, Michael Trauner, Petra Steindl-Munda, Harald Hofer, Peter Ferenci
BACKGROUND: The introduction of direct-acting antivirals (DAA) has increased sustained virological response (SVR) rates in patients with advanced liver disease and chronic hepatitis C(CHC)infection. At present, data on clinical outcome and long-term durability of viral eradication after successful DAA therapy are scarce. AIM: To evaluate the long-term success of viral eradication in patients with advanced fibrosis or cirrhosis treated with DAAs. METHODS: Five hundred and fifty one patients with advanced fibrosis (n=158) or liver cirrhosis (CPS-A:317,CPS-B/C:76) and SVR after interferon and ribavirin-free DAA therapy treated between October 2013 and April 2016 were studied with a median follow-up of 65...
November 14, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29135574/interferon-free-therapy-for-treating-hcv-in-difficult-to-treat-hiv-coinfected-patients-as-implemented-in-routine-medical-practice
#7
Carlos Mínguez, Miguel García-Deltoro, Juan Flores, Maria-José Galindo, Marta Montero, Sergio Reus, Jorge Carmena, Mar Masiá, Concepción Amador, Enrique Ortega
BACKGROUND/AIMS: Data regarding the use of all-oral direct-acting antivirals (DAA) in HIV/HCV-coinfected patients with advanced liver fibrosis are required, because they are generally under-represented in clinical trials. This study sought to evaluate the use of these drugs in a cohort of coinfected patients, mostly with factors that have previously been recognised as predictors of treatment failure. METHODS: COINFECOVA-2 is an observational, multicenter study conducted in Eastern Spain...
November 10, 2017: AIDS
https://www.readbyqxmd.com/read/29135370/pharmacokinetics-based-adjusted-versus-standard-dose-of-ribavirin-does-not-improve-virologic-response-rates-in-chronic-hepatitis-c-genotype-4-patients-a-randomized-controlled-trial
#8
Ibrahim H Altraif, Faisal Sanai, Mohammed A Babatin, Abduljaleel A Alalwan, Ayman A Abdo, Waleed Alhamoudi, Musthafa Peedikayil, Hamdan Alghamdi, Fahad Alsohaibani, Khalid A Alswat, Shazia Murtaza, Abdullah Alghamdi, Sara Altraif, Abdulrahman Aljumah, Fayaz A Handoo, Abdulkareem M AlBekairy, Hamad I Al-Ashgar, Mohammed Alquaiz, Mohammed A Alblawi, Waleed AlTamimi, Véronique Loustaud-Ratti, Pierre Marquett
Optimal doses of Ribavirin (RBV) for hepatitis C virus (HCV) treatment are not known. To assess the safety and efficacy of PegIFNalfa-2a in combination with an adjusted (ADJ) RBV dose based on early pharmacokinetics versus a fixed standard (STD) dose of RBV in chronic HCV genotype (GT) 4-naive patients in a randomized trial. One hundred eighty-one patients were randomized. The baseline variables were similar in both arms and females were 50.3% of the patients, 76.5% had minimal-moderate fibrosis (F0-2). Sustained virologic response (SVR) was achieved in 99 (54...
November 2017: Journal of Interferon & Cytokine Research
https://www.readbyqxmd.com/read/29126899/merimepodib-an-impdh-inhibitor-suppresses-replication-of-zika-virus-and-other-emerging-viral-pathogens
#9
Xiao Tong, Jeanon Smith, Natalya Bukreyeva, Takaaki Koma, John T Manning, Raj Kalkeri, Ann D Kwong, Slobodan Paessler
Zika virus (ZIKV), a member of the Flaviviridae family, has recently been linked to abnormal pregnancies, fetal death, microcephaly, and Guillain-Barré syndrome in humans. Merimepodib (MMPD, VX-497), a potent inhibitor of inosine-5'-monophosphate dehydrogenase (IMPDH), has shown antiviral activity against HCV and a variety of DNA and RNA viruses in vitro. In this report, we expand the antiviral spectrum of MMPD, and demonstrate that MMPD inhibits ZIKV RNA replication with an EC50 of 0.6 μM. Furthermore, MMPD reduces the virus production of ZIKV as well as several other important emerging viral pathogens such as Ebola, Lassa, Chikungunya, and Junin viruses...
November 8, 2017: Antiviral Research
https://www.readbyqxmd.com/read/29125670/use-of-a-hepatitis-c-virus-hcv-rna-positive-donor-in-a-treated-hcv-rna-negative-liver-transplant-recipient
#10
Isabel Campos-Varela, Eliana Z Agudelo, Monika Sarkar, John P Roberts, Norah A Terrault
The shortage of livers has led most transplant centers to use extended criteria donors. Hepatitis C virus (HCV) RNA-positive donors are typically not given to patients who have cleared HCV. A 64-year-old male with chronic hepatitis C, genotype 1b was listed for LT with hepatocellular carcinoma. While on the waiting list, the patient was treated with sofosbuvir, ledipasvir, and ribavirin and achieved an HCV RNA <15 IU/mL by week 10. At week 18 of a planned 24-week treatment course, the patient underwent deceased-donor LT and received an organ from an anti-HCV-positive donor...
November 10, 2017: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/29120906/efficacy-of-ledipasvir-sofosbuvir-plus-ribavirin-for-12-weeks-in-patients-with-chronic-hepatitis-c-genotype-3-and-compensated-liver-disease
#11
Stephan Moser, Karin Kozbial, Hermann Laferl, Angelika Schütz, Thomas Reiberger, Philipp Schwabl, Enisa Gutic, Cornelia Schwanke, Raphael Schubert, Julian Luhn, Tobias Lang, Michael Schleicher, Petra Steindl-Munda, Hans Haltmayer, Peter Ferenci, Michael Gschwantler
INTRODUCTION: In the era of direct-acting antivirals, hepatitis C virus (HCV) genotype (GT) 3 remains as the most difficult-to-treat HCV-GT. Currently, data on the efficacy of ledipasvir/sofosbuvir plus ribavirin (SOF/LDV+RBV) in GT3-infected patients are limited. We investigated the efficacy of this regimen in a real-life cohort from Austria. PATIENTS AND METHODS: A total of 55 patients with HCV-GT3 and compensated liver disease (20% treatment-experienced, 33% with cirrhosis, 7% with HIV coinfection) from four Austrian hepatitis centers received treatment with SOF/LDV+RBV for 12 weeks...
November 8, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29119253/higher-expression-of-inhibitory-cd158b-and-cd158e-nk-cell-receptor-and-age-predicts-treatment-response-in-children-with-chronic-hepatitis-c
#12
Anna Mania, Mariusz Kaczmarek, Paweł Kemnitz, Katarzyna Mazur-Melewska, Magdalena Figlerowicz, Jan Sikora, Wojciech Służewski, Jan Żeromski
Treatment with pegylated interferon-α and ribavirin (PEG-IFN/RBV) is the only choice for chronic hepatitis C (CHC) in children. Natural killer (NK) cells were described to play a vital role in CHC. The aim of this study was to analyze the expression of peripheral blood NK cell receptors in their relation to PEG-IFN/RBV treatment response. Study included 26 children with CHC-13 boys, age range 13.42 ± 3.28 years. Blood for biochemical, virological and cytometric testing was taken for evaluation prior to the antiviral treatment...
November 8, 2017: Medical Microbiology and Immunology
https://www.readbyqxmd.com/read/29117665/application-of-therapeutic-plasma-exchange-in-patients-having-severe-fever-with-thrombocytopenia-syndrome
#13
Jeong Rae Yoo, Sun Hyung Kim, Young Ree Kim, Keun Hwa Lee, Won Sup Oh, Sang Taek Heo
Background/Aims: Severe fever with thrombocytopenia syndrome (SFTS) is a viral hemorrhagic fever with a high fatality rate. However, effective treatments for SFTS cases not responded to supportive therapy have not been established. Herein, we introduced the therapeutic plasma exchange (TPE) in SFTS patients in a tertiary hospital between 2013 and 2015. Methods: TPE was performed in patients with rapidly progressing SFTS. Clinical, laboratory, and virological parameters were compared before and after TPE...
November 10, 2017: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/29116287/peginterferon-still-has-a-place-in-the-treatment-of-hepatitis-c-caused-by-genotype-3-virus
#14
Aline Vitali Grando, Paulo Roberto Abrão Ferreira, Mário Guimarães Pessôa, Daniel Ferraz de Campos Mazo, Carlos Eduardo Brandão-Mello, Tânia Reuter, Ana de Lourdes Candolo Martinelli, Mário Peribanez Gonzalez, Ana Catharina Seixas-Santos Nastri, Aléia Faustina Campos, Max Igor Banks Ferreira Lopes, José David Urbaez Brito, Maria Cássia Mendes-Corrêa
Despite recent advances in therapy for chronic hepatitis C (CHC), the disease caused by genotype 3 virus (GEN3) is still considered a treatment challenge in certain patient subgroups. The aim of this retrospective study was to evaluate the effectiveness and safety of the peginterferon (Peg-IFN) and ribavirin (RBV) combination treatment for GEN3/CHC patients, and to evaluate sustained virological response (SVR) indicators and early treatment interruption due to serious adverse events (SAE). This was a retrospective observational study of GEN3/CHC patients, co-infected or not by HIV and treated with Peg-IFN/RBV in nine Brazilian healthcare centers...
November 6, 2017: Revista do Instituto de Medicina Tropical de São Paulo
https://www.readbyqxmd.com/read/29113824/comparative-analysis-of-different-cell-systems-for-zika-virus-zikv-propagation-and-evaluation-of-anti-zikv-compounds-in-vitro
#15
Ilaria Vicenti, Adele Boccuto, Alessia Giannini, Filippo Dragoni, Francesco Saladini, Maurizio Zazzi
A strong correlation between Zika virus (ZIKV) infection and severe neurological disease in newborns and occasionally adults has emerged in the Brazilian outbreak. Efficient human cell-based assays are required to test candidate inhibitors of ZIKV replication. The aim of this work was to investigate ZIKV propagation and quantification in different cell lines. The human (U87, A549, Huh7), mosquito (C6/36) and monkey (VERO E6) cell lines tested were all permissive to ZIKV infection. When assessed by plaque forming units (PFU) in three different target cell lines, the maximal production of ZIKV was achieved in Huh7 at day 3 post-infection (6...
November 4, 2017: Virus Research
https://www.readbyqxmd.com/read/29112331/intrapatient-viral-diversity-and-treatment-outcome-in-patients-with-genotype-3a-hepatitis-c-virus-infection-on-sofosbuvir-containing-regimens
#16
Neeru Bhardwaj, Manon Ragonnet-Cronin, Ben Murrell, Krishna Chodavarapu, Ross Martin, Silvia Chang, Michael D Miller, Jordan J Feld, Mark Sulkowski, Alessandra Mangia, Joel O Wertheim, Anu Osinusi, John McNally, Diana Brainard, Hongmei Mo, Evguenia S Svarovskaia
Treatment with the direct-acting antiviral agent (DAA) sofosbuvir (SOF), an NS5B inhibitor, and velpatasvir (VEL), an NS5A inhibitor, demonstrates viral cure rates of ≥95% in hepatitis C virus (HCV) genotypes (GT) 1-6. Here we investigated intrapatient HCV diversity in NS5A and NS5B using Shannon entropy to examine the relationship between viral diversity and treatment outcome. At baseline, HCV diversity was lowest in patients infected with HCV GT3 as compared to the other GTs, and viral diversity was greater in NS5A than NS5B (p<0...
November 7, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29112301/ribavirin-augments-doxorubicin-s-efficacy-in-human-hepatocellular-carcinoma-through-inhibiting-doxorubicin-induced-eif4e-activation
#17
Jun Tan, Jingfen Ye, Meijun Song, Mi Zhou, Yaoren Hu
Activation of eukaryotic translation initiation factor 4E (eIF4E) is a cellular survival mechanism in response to chemotherapy in cancers. In this work, we demonstrate that targeting eIF4E by ribavirin sensitizes hepatocellular carcinoma (HCC) cell response to doxorubicin. Ribavirin inhibits growth and survival of HCC cells, and to a greater extent than in normal liver cells. Its combination with doxorubicin achieves greater efficacy than single drug in vitro and in vivo. Ribavirin suppresses phosphorylation of molecules involved in Akt/mTOR/eIF4E pathway...
November 7, 2017: Journal of Biochemical and Molecular Toxicology
https://www.readbyqxmd.com/read/29109164/zika-virus-zikv-replication-is-substantially-inhibited-by-novel-favipiravir-and-interferon-alpha-combination-regimens
#18
Camilly P Pires de Mello, Xun Tao, Tae Hwan Kim, Jürgen B Bulitta, Jaime L Rodriquez, Justin J Pomeroy, Ashley N Brown
Zika virus (ZIKV) is a major public health concern due to its overwhelming spread into the Americas. Currently there are neither licensed vaccines nor antiviral therapies available for the treatment of ZIKV. We aimed to identify and rationally optimize effective therapeutic regimens for ZIKV by evaluating the antiviral potential of approved broad-spectrum antiviral agents favipiravir (FAV), interferon-alpha (IFN), and ribavirin (RBV) as single agent and combinations. For these studies, Vero cells were infected with ZIKV in the presence of increasing concentrations of FAV, IFN, or/and RBV for four days...
November 6, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29108516/clinical-outcomes-of-paramyxovirus-infections-in-lung-transplant-recipients-treated-with-oral-ribavirin-a-two-center-case-series
#19
Bryan Garcia, Nirmal Sharma, Kevin Johnson, Juan Salgado, Keith Wille
OBJECTIVES: Paramyxoviruses contribute to morbidity and mortality after lung transplant and are associated with bronchiolitis obliterans syndrome. Oral ribavirin has been used off-label for treatment of paramyxoviruses in immunosuppressed patients; however, data supporting its use for this purpose are lacking. MATERIALS AND METHODS: We conducted a retrospective review to evaluate clinical outcomes of lung transplant recipients infected with paramyxoviruses and received treatment with oral ribavirin at 2 tertiary referral centers...
October 31, 2017: Experimental and Clinical Transplantation
https://www.readbyqxmd.com/read/29105131/editorial-ribavirin-continues-to-play-a-role-in-treatment-with-direct-acting-antivirals-for-hepatitis-c-virus-infected-patients-with-decompensated-cirrhosis
#20
EDITORIAL
J Waldenström, M Lagging
No abstract text is available yet for this article.
December 2017: Alimentary Pharmacology & Therapeutics
keyword
keyword
29712
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"